Analysts and Calls -- Lehman Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- Lehman

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who started this subject	10/15/2003 11:37:53 AM
From: nigel bates	of 30

FTSE TechMARK movers: Celltech gets broker's leg-up LONDON (ShareCast) - Celltech (LSE: CCH.L - news - msgs) got a lift from a bullish note from Lehman Brothers. The broker has raised its price target to 500p from 410p, after Phase II clinical trial data from Germany's Schering suggested its treatment for Crohn's disease might struggle to compete with Celltech's drug in trials, CDP 870. CDP 870 might also be useful as a treatment for rheumatoid arthritis, the broker said...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next